Divergent roles of GSK3 and CDK5 in APP processing

Biochemical and Biophysical Research Communications

Volumn 312, Issue 4, 2003, Pages 922-929

  Ryder, John ^a   Su, Yuan ^a   Liu, Feng ^a   Li, Baolin ^a   Zhou, Yan ^a   Ni, Binhui ^a,b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Antisense; APP; A ; CDK5; GSK3

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CELL ENZYME; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; LY 379196; ROSCOVITINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS;

EID: 0344926464     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.11.014     Document Type: Article

References (32)

1. Morris J.C., Storandt M., McKeel D.W. Jr., Rubin E.H., Price J.L., Grant E.A., Berg L. Cerebral amyloid deposition and diffuse plaques in 'normal' aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 46:1996;707-719.
2. Selkoe D.J. The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. Neurol. Clin. 18:2000;903-922.
3. Imahori K., Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem. (Tokyo). 121:1997;179-188.
4. Anderton B.H., Betts J., Blackstock W.P., Brion J.P., Chapman S., Connell J., Dayanandan R., Gallo J.M., Gibb G., Hanger D.P., Hutton M., Kardalinou E., Leroy K., Lovestone S., Mack T., Reynolds C.H., Van Slegtenhorst M. Sites of phosphorylation in tau and factors affecting their regulation. Biochem. Soc. Symp. 2001;73-80.
5. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:1996;710-713.
6. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G., Sisodia S.S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 17:1996;1005-1013.
7. Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., Selkoe D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 398:1999;513-517.
8. Tesco G., Tanzi R.E. GSK3 beta forms a tetrameric complex with endogenous PS1-CTF/NTF and beta-catenin. Effects of the D257/D385A and FAD-linked mutations. Ann. N. Y. Acad. Sci. 920:2000;227-232.
9. Aplin A.E., Gibb G.M., Jacobsen J.S., Gallo J.M., Anderton B.H. In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J. Neurochem. 67:1996;699-707.
10. Iijima K., Ando K., Takeda S., Satoh Y., Seki T., Itohara S., Greengard P., Kirino Y., Nairn A.C., Suzuki T. Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. J. Neurochem. 75:2000;1085-1091.
11. Suzuki T., Oishi M., Marshak D.R., Czernik A.J., Nairn A.C., Greengard P. Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein. EMBO J. 13:1994;1114-1122.
12. Liu F., Su Y., Li B., Zhou Y., Ryder J., Gonzalez-DeWhitt P., May P.C., Ni B. Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett. 547:2003;193-196.
13. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 107:1980;519-527.
14. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359:2001;1-16.
15. Paglini G., Caceres A. The role of the Cdk5-p35 kinase in neuronal development. Eur. J. Biochem. 268:2001;1528-1533.
16. Grant P., Sharma P., Pant H.C. Cyclin-dependent protein kinase 5 (Cdk5) and the regulation of neurofilament metabolism. Eur. J. Biochem. 268:2001;1534-1546.
17. Maccioni R.B., Munoz J.P., Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. 32:2001;367-381.
18. Flaherty D.B., Soria J.P., Tomasiewicz H.G., Wood J.G. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J. Neurosci. Res. 62:2000;463-472.
19. Sengupta A., Wu Q., Grundke-Iqbal I., Iqbal K., Singh T.J. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol. Cell. Biochem. 167:1997;99-105.
20. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 359:1992;325-327.
21. ′ -deoxy gaps as antisense inhibitors of gene expression J. Biol. Chem. 268:1993;14514-14522.
22. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21:2001;372-381.
23. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356.
24. Oltersdorf T., Ward P.J., Henriksson T., Beattie E.C., Neve R., Lieberburg I., Fritz L.C. The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway. J. Biol. Chem. 265:1990;4492-4497.
25. Hers I., Tavare J.M., Denton R.M. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett. 460:1999;433-436.
26. Phiel C.J., Klein P.S. Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 41:2001;789-813.
27. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:1997;527-536.
28. Sun X., Sato S., Murayama O., Murayama M., Park J.M., Yamaguchi H., Takashima A. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci. Lett. 321:2002;61-64.
29. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 423:2003;435-439.
30. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:1995;523-527.
31. Su Y., Ni B. Selective deposition of amyloid-beta protein in the entorhinal-dentate projection of a transgenic mouse model of Alzheimer's disease. J. Neurosci. Res. 53:1998;177-186.
32. Zhang F., Phiel C.J., Spece L., Gurvich N., Klein P.S. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J. Biol. Chem. 278:2003;33067-33077.